Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)
- Conditions
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- John Rieth
- Target Recruit Count
- 8
- Registration Number
- NCT06113809
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 779
- Registration Number
- NCT06086340
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 54
- Registration Number
- NCT06076772
- Locations
- 🇸🇦
Asmaa Imam Ahmed, Al Madīnah, AL, Saudi Arabia
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1050
- Registration Number
- NCT06065748
- Locations
- 🇺🇸
Sutter Health Medical Center, Sacramento, California, United States
🇩🇪Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie, Bamberg, Germany
🇬🇷Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Lebanese University
- Target Recruit Count
- 500
- Registration Number
- NCT06065592
- Locations
- 🇱🇧
Haykel Hospital, Tripoli, North Lebanon, Lebanon
🇱🇧Lebanese University, Tripoli, North Lebanon, Lebanon
A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 472
- Registration Number
- NCT06003114
- Locations
- 🇨🇦
Alberta Health Services, Edmonton, Alberta, Canada
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 30
- Registration Number
- NCT05949424
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- NiKang Therapeutics, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05935748
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of AVZO-021 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Avenzo Therapeutics, Inc.
- Target Recruit Count
- 430
- Registration Number
- NCT05867251
- Locations
- 🇺🇸
NEXT Virginia, Fairfax, Virginia, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sidney Kimmel Cancer Center (SKCC) at Jefferson Health, Philadelphia, Pennsylvania, United States
Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- AIPING ZHOU
- Target Recruit Count
- 30
- Registration Number
- NCT05865132
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.